369 related articles for article (PubMed ID: 27086917)
1. Lapatinib-loaded human serum albumin nanoparticles for the prevention and treatment of triple-negative breast cancer metastasis to the brain.
Wan X; Zheng X; Pang X; Pang Z; Zhao J; Zhang Z; Jiang T; Xu W; Zhang Q; Jiang X
Oncotarget; 2016 Jun; 7(23):34038-51. PubMed ID: 27086917
[TBL] [Abstract][Full Text] [Related]
2. The potential use of lapatinib-loaded human serum albumin nanoparticles in the treatment of triple-negative breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Jing T; Xu W; Zhang Q
Int J Pharm; 2015 Apr; 484(1-2):16-28. PubMed ID: 25700543
[TBL] [Abstract][Full Text] [Related]
3. Incorporation of lapatinib into human serum albumin nanoparticles with enhanced anti-tumor effects in HER2-positive breast cancer.
Wan X; Zheng X; Pang X; Zhang Z; Zhang Q
Colloids Surf B Biointerfaces; 2015 Dec; 136():817-27. PubMed ID: 26539808
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting the proliferation, migration and invasion of triple negative breast cancer cells through anti-tumor human serum albumin nanoparticles loading aziditaxel as a novel taxane derivative.
Chen LQ; Zhang ZM; Huang W; Gao ZG; Fang WS; Jin MJ; Yu L
Pharmazie; 2017 Mar; 72(3):152-160. PubMed ID: 29442050
[TBL] [Abstract][Full Text] [Related]
5. A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Hu H; Lin Z; He B; Dai W; Wang X; Wang J; Zhang X; Zhang H; Zhang Q
J Control Release; 2015 Dec; 220(Pt A):189-200. PubMed ID: 26474677
[TBL] [Abstract][Full Text] [Related]
6. Lapatinib inhibits CIP2A/PP2A/p-Akt signaling and induces apoptosis in triple negative breast cancer cells.
Liu CY; Hu MH; Hsu CJ; Huang CT; Wang DS; Tsai WC; Chen YT; Lee CH; Chu PY; Hsu CC; Chen MH; Shiau CW; Tseng LM; Chen KF
Oncotarget; 2016 Feb; 7(8):9135-49. PubMed ID: 26824320
[TBL] [Abstract][Full Text] [Related]
7. Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation.
Andey T; Sudhakar G; Marepally S; Patel A; Banerjee R; Singh M
Mol Pharm; 2015 Apr; 12(4):1105-20. PubMed ID: 25661724
[TBL] [Abstract][Full Text] [Related]
8. Incorporation of lapatinib into core-shell nanoparticles improves both the solubility and anti-glioma effects of the drug.
Gao H; Wang Y; Chen C; Chen J; Wei Y; Cao S; Jiang X
Int J Pharm; 2014 Jan; 461(1-2):478-88. PubMed ID: 24368101
[TBL] [Abstract][Full Text] [Related]
9. Distribution analysis of epertinib in brain metastasis of HER2-positive breast cancer by imaging mass spectrometry and prospect for antitumor activity.
Tanaka Y; Hirata M; Shinonome S; Torii M; Nezasa KI; Tanaka H
Sci Rep; 2018 Jan; 8(1):343. PubMed ID: 29321587
[TBL] [Abstract][Full Text] [Related]
10. Blood-brain barrier-penetrating amphiphilic polymer nanoparticles deliver docetaxel for the treatment of brain metastases of triple negative breast cancer.
He C; Cai P; Li J; Zhang T; Lin L; Abbasi AZ; Henderson JT; Rauth AM; Wu XY
J Control Release; 2017 Jan; 246():98-109. PubMed ID: 28017889
[TBL] [Abstract][Full Text] [Related]
11. Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival.
Werfel TA; Wang S; Jackson MA; Kavanaugh TE; Joly MM; Lee LH; Hicks DJ; Sanchez V; Ericsson PG; Kilchrist KV; Dimobi SC; Sarett SM; Brantley-Sieders DM; Cook RS; Duvall CL
Cancer Res; 2018 Apr; 78(7):1845-1858. PubMed ID: 29358172
[TBL] [Abstract][Full Text] [Related]
12. Aminoflavone-loaded EGFR-targeted unimolecular micelle nanoparticles exhibit anti-cancer effects in triple negative breast cancer.
Brinkman AM; Chen G; Wang Y; Hedman CJ; Sherer NM; Havighurst TC; Gong S; Xu W
Biomaterials; 2016 Sep; 101():20-31. PubMed ID: 27267625
[TBL] [Abstract][Full Text] [Related]
13. Treating metastatic triple negative breast cancer with CD44/neuropilin dual molecular targets of multifunctional nanoparticles.
Liang DS; Zhang WJ; Wang AT; Su HT; Zhong HJ; Qi XR
Biomaterials; 2017 Aug; 137():23-36. PubMed ID: 28528300
[TBL] [Abstract][Full Text] [Related]
14. Lapatinib increases motility of triple-negative breast cancer cells by decreasing miRNA-7 and inducing Raf-1/MAPK-dependent interleukin-6.
Hsiao YC; Yeh MH; Chen YJ; Liu JF; Tang CH; Huang WC
Oncotarget; 2015 Nov; 6(35):37965-78. PubMed ID: 26513016
[TBL] [Abstract][Full Text] [Related]
15. Hydrophobic interaction mediating self-assembled nanoparticles of succinobucol suppress lung metastasis of breast cancer by inhibition of VCAM-1 expression.
Cao H; Zhang Z; Zhao S; He X; Yu H; Yin Q; Zhang Z; Gu W; Chen L; Li Y
J Control Release; 2015 May; 205():162-71. PubMed ID: 25598420
[TBL] [Abstract][Full Text] [Related]
16. Novel nanosystem to enhance the antitumor activity of lapatinib in breast cancer treatment: Therapeutic efficacy evaluation.
Huo ZJ; Wang SJ; Wang ZQ; Zuo WS; Liu P; Pang B; Liu K
Cancer Sci; 2015 Oct; 106(10):1429-37. PubMed ID: 26177628
[TBL] [Abstract][Full Text] [Related]
17. Synergistic inhibition of breast cancer metastasis by silibinin-loaded lipid nanoparticles containing TPGS.
Xu P; Yin Q; Shen J; Chen L; Yu H; Zhang Z; Li Y
Int J Pharm; 2013 Sep; 454(1):21-30. PubMed ID: 23830941
[TBL] [Abstract][Full Text] [Related]
18. Mitochondria Targeting and Destabilizing Hyaluronic Acid Derivative-Based Nanoparticles for the Delivery of Lapatinib to Triple-Negative Breast Cancer.
Lee SY; Cho HJ
Biomacromolecules; 2019 Feb; 20(2):835-845. PubMed ID: 30566834
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib: a small-molecule inhibitor of epidermal growth factor receptor and human epidermal growth factor receptor-2 tyrosine kinases used in the treatment of breast cancer.
Tevaarwerk AJ; Kolesar JM
Clin Ther; 2009; 31 Pt 2():2332-48. PubMed ID: 20110044
[TBL] [Abstract][Full Text] [Related]
20. Lapatinib inhibits doxorubicin induced migration of HER2-positive breast cancer cells.
Chintalaramulu N; Vadivelu R; Nguyen NT; Cock IE
Inflammopharmacology; 2020 Oct; 28(5):1375-1386. PubMed ID: 32378049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
